Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Par Drugs and Chemicals's EBIT per Share for the
three
months ended in Mar. 2026 was ₹0.71.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹14.16.
During the past 12 months, the average EBIT per Share Growth Rate of Par Drugs and Chemicals was -15.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -2.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Par Drugs and Chemicals's EBIT per Share or its related term are showing as below:
NSE:PAR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -2.7 Med: 15.3 Max: 39.5
Current: -2.7
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Par Drugs and Chemicals was 39.50% per year. The lowest was -2.70% per year. And the median was 15.30% per year.
NSE:PAR's 3-Year EBIT Growth Rate is ranked worse than 65.47% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:PAR: -2.70
Par Drugs and Chemicals (NSE:PAR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Par Drugs and Chemicals EBIT per Share Related Terms
Par Drugs and Chemicals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Par Drugs and Chemicals (NSE:PAR) has a EBIT per Share of ₹14.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Par Drugs and Chemicals and its competitors. According to the industry distribution chart, Par Drugs and Chemicals ranks #531 out of 811 companies in the Drug Manufacturers industry, placing it in the top 65.5%.
Is Par Drugs and Chemicals' EBIT per Share too high?
Par Drugs and Chemicals' current EBIT per Share is ₹14.16. Based on the distribution chart, Par Drugs and Chemicals ranks #531 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Par Drugs and Chemicals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #531 out of 811 companies for EBIT per Share. This places Par Drugs and Chemicals in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Par Drugs and Chemicals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Par Drugs and Chemicals's current EBIT per Share is ₹14.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.93, compared to a current price of ₹102.26 — trading 50.8% below its estimated fair value. The current EBIT per Share is ₹14.16. Par Drugs and Chemicals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current EBIT per Share is ₹14.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?
Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued.
The current stock price of ₹102.26 is trading 50.8% below its estimated GF Value™ of ₹207.93.
GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.
Key valuation signals for NSE:PAR:
EBIT per Share: ₹14.16
GF Value™: ₹207.93 vs. price of ₹102.26 (50.8% below fair value)
No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
81GF Score
Get the complete analysis for NSE:PAR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PAR has been successfully added to your 
